Alastair D. Reith

GlaxoSmithKline (United Kingdom) — United Kingdom

Medicine · Health Sciences

37h-index10.8kcitations85works0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Parkinson's Disease Mechanisms and Treatments(24), Protein Kinase Regulation and GTPase Signaling(10), Cellular transport and secretion(9), Cancer-related gene regulation(9), Wnt/β-catenin signaling in development and cancer(8)

Publications81 total

Repurposed Drug Prioritisation Pipeline for an Alzheimer’s Disease Multi‐arm Platform Trial
Alzheimer s & Dementia·2025Open Access
Discovery and optimization of pyrrolopyrimidines as highly potent, selective and brain-penetrant LRRK2 inhibitors
RSC Medicinal Chemistry·2025Open Access
Tau uptake by human neurons depends on receptor LRP1 and kinase LRRK2
The EMBO Journal·2025· 3 citedOpen Access
A community-led initiative to de-risk and advance Parkinson’s disease therapeutic targets
npj Parkinson s Disease·2025· 2 citedOpen Access
A CRISPR-CAS9 high throughput machine-learning platform for modulation of genes involved in Parkinson’s disease-associated PINK1-mitophagy in iPSC-derived dopaminergic neurons
2025Open Access
Author Reply to Peer Reviews of Whole genome CRISPR screens identify a LRRK2-regulated pathway for extracellular tau uptake by human neurons
2025
Impact of Type II LRRK2 inhibitors on signalling and mitophagy
2021Open Access
Impact of Type II LRRK2 inhibitors on signaling and mitophagy
Biochemical Journal·2021· 66 citedOpen Access
Impact of Type II LRRK2 inhibitors on signalling and mitophagy
Zenodo (CERN European Organization for Nuclear Research)·2021Open Access
Pharmacological rescue of impaired mitophagy in Parkinson’s disease-related LRRK2 G2019S knock-in mice
eLife·2021· 128 citedOpen Access
Author response: Pharmacological rescue of impaired mitophagy in Parkinson’s disease-related LRRK2 G2019S knock-in mice
2021· 1 citedOpen Access
Impact of Type II LRRK2 inhibitors on signalling and mitophagy
2021· 3 citedOpen Access
Pharmacological rescue of impaired mitophagy in Parkinson’s disease-related LRRK2 G2019S knock-in mice
2020· 7 citedOpen Access
Whole genome CRISPR screens identify a LRRK2-regulated pathway for extracellular tau uptake by human neurons
2020· 20 citedOpen Access
Basic clinical features do not predict dopamine transporter binding in idiopathic REM behavior disorder
npj Parkinson s Disease·2019· 30 citedOpen Access
5-Substituted-N-pyridazinylbenzamides as potent and selective LRRK2 inhibitors: Improved brain unbound fraction enables efficacy
Bioorganic & Medicinal Chemistry Letters·2018· 14 citedOpen Access
LRRK2 is a negative regulator of <i>Mycobacterium tuberculosis</i> phagosome maturation in macrophages
The EMBO Journal·2018· 178 citedOpen Access
Discovery of 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amines as potent, selective and orally bioavailable LRRK2 inhibitors
Bioorganic & Medicinal Chemistry Letters·2018· 19 citedOpen Access
Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors
Bioorganic & Medicinal Chemistry Letters·2017· 22 citedOpen Access
Phos-tag analysis of Rab10 phosphorylation by LRRK2: a powerful assay for assessing kinase function and inhibitors
Biochemical Journal·2016· 178 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Dario R. Alessi(8), Alan Bernstein(8), Ainsley A. Culbert(7), Darren A.E. Cross(5), Murray J. B. Brown(5), Patrice Dubreuil(4), C. Edge(4), Luigi Stasi(4), Francesca Tonelli(3), Genta Ito(3), Paul Davies(3), Matthias Trost(3), Graham Duddy(3), Marco A. S. Baptista(3), Paul S. Carter(3), Stephen D. Skaper(3), Robert Rottapel(3), Lesley M. Forrester(3), Paul Bamborough(3), B.D. Bax(3)